Neumirna Aims EIC Accelerator Support at Drug-Resistant Epilepsy
About 50 million people live with epilepsy, and the World Health Organization says up to 70% of them could become seizure-free with the right antiseizure medicines. The rest are the market for Neumirna Therapeutics, a Copenhagen company whose lead drug, NMT.001, tries to switch off one small RNA molecule in the brain instead of damping seizures the way existing pills do. Its own scientists put drug-resistant epilepsy at 30% to 35% of people with the disease, in an abstract for the American Epilepsy Society in December 2025.
On 16 November 2026 the EIC published the companies picked from its May and July 2026 cut-offs, and Neumirna's project ADMIRE, "Antisense-Oligonucleotide Development for miR-134 Inhibition in Refractory Epilepsy", is on the list for the batch covering the May and July 2026 cut-offs, recommended for blended finance. Selection is not yet a contract: the EIC says grant agreements are expected within three months, so this article sets out what the company promises and what can already be checked.
Company file
- Legal entity
- Neumirna Therapeutics ApS, CVR 41696451, a Danish private limited company
- Founded
- 21 September 2020, per the Danish business register; spin-out from Aalborg University
- Headquarters
- A.C. Meyers Vænge 15, Copenhagen SV
- Founders
- Henrik Klitgaard, Sakari Kauppinen and Lars Hellerung Christiansen
- CEO
- Ellen K. Donnelly, registered as CEO since 15 September 2025
- Known investors
- Angelini Ventures, Invivo Partners, Innovestor Life Science Fund, Sunstone Life Science Ventures (seed)
- EIC project
- ADMIRE, May/July 2026 cut-off batch, blended finance, grant agreement pending
- Lead asset
- NMT.001, an antisense oligonucleotide against miR-134, preclinical
One microRNA, discovered in Dublin
MicroRNAs are short strands of RNA that switch off groups of genes, and miR-134 is one that is active only in the brain. In 2012 a team led from the Royal College of Surgeons in Ireland reported in Nature Medicine that miR-134 is raised in human and experimental epilepsy, and that silencing it in mice after an episode of status epilepticus cut later spontaneous seizures by more than 90%. The authors wrote that whether this was an anticonvulsant or a truly antiepileptogenic effect needed more experiments.
Neumirna turns that finding into a drug candidate. NMT.001 is a mixmer antisense oligonucleotide, a short synthetic strand built to bind miR-134 and block it, according to the company's 2025 conference abstract. David Henshall, director of the Irish research centre FutureNeuro and a professor at RCSI, told Silicon Republic in January 2025 that the link between the microRNA and epilepsy "originated here at RCSI" and that FutureNeuro partnered with Neumirna to pick the candidate.
The approach differs from today's antiseizure medicines in what it claims to do. The company describes NMT.001 as targeting the disease rather than the symptoms. That is a claim tested so far only in animals and cells, and the clinical study that would test it in people has not started, according to the company's own timeline.
Where the evidence comes from
The data on NMT.001 are in conference abstracts written by Neumirna staff with RCSI, Aalborg University and University of Glasgow co-authors: a 2023 abstract on mice with chronic epilepsy, a 2024 abstract covering mice, dogs and human tissue, and two 2025 abstracts on safety and on behaviour. Abstracts are not peer-reviewed papers. Searches on 16 November 2026 found no journal article reporting NMT.001 efficacy data.
What the animal data say
In the 2023 abstract, the most potent compound from a screening library reduced spontaneous seizures in mice that had already developed chronic epilepsy, with the effect starting within days and lasting through about two months of recording. The 2024 abstract reports disease modification in an NIH-validated mouse model of drug-resistant epilepsy and says interim results from METriC, a veterinary trial in dogs with naturally occurring drug-resistant epilepsy funded by the US charity CURE Epilepsy, look similar. It gives no number of dogs and no figures.
The December 2025 safety abstract is the most specific. One injection into the brain's fluid-filled ventricles left 67% of mice seizure-free "beyond the window of drug exposure". Mice tolerated up to 20 times the active dose with no treatment-related findings. In non-human primates, doses of 30 mg and above caused acute neurological effects that faded within 24 hours, and histopathology was not yet available when the abstract was written. A second 2025 abstract reports that a single 1 nmol dose reversed behavioural changes in epileptic mice up to 64 days later.
"This funding is essential to bring NMT.001 to clinical trials and advance our pipeline."
Janine Erler, then CEO, in the Series A press release, 8 January 2025A spin-out that changed chief executive twice
Neumirna was founded in 2020 as a spin-out from Aalborg University, where co-founder Sakari Kauppinen directs the Center for RNA Medicine. The register's role history records co-founder Henrik Klitgaard as chief executive from 21 September 2020, Janine Erler from 1 November 2023 and Ellen Kinson Donnelly from 15 September 2025; the company's news page announced Donnelly on 18 September 2025. Luis Pareras of Invivo Partners has chaired the board since 10 January 2025.
The hires since then point to the clinic. The company announced Ina Brünig-Traebert as chief development officer in July 2025, Ferenc Tracik as chief medical officer in April 2026 and Disa Tehler as head of RNA therapeutics in September 2026. Tracik led the European medical launch of Biogen's antisense drug for spinal muscular atrophy, according to a BioIndustry Association notice of 20 May 2026, which says he will help guide NMT.001 "into the clinic in early 2027".
The record
Fourteen years from a mouse study to a planned first human trial
The miR-134 finding dates from 2012; Neumirna was registered in 2020, raised its Series A in 2025 and plans to enter the clinic in early 2027. Dates after November 2026 are company plans.
- Jul 2012Target publishedRCSI-led study in Nature Medicine: silencing miR-134 cut later spontaneous seizures in mice by more than 90%
- Sep 2020Company registeredNeumirna Therapeutics ApS registered in Denmark on 21 September 2020 as an Aalborg University spin-out
- Late 2022Seed loanSunstone invests a convertible loan€400,000
- Nov 2023New CEOJanine Erler registered as chief executive from 1 November 2023
- Dec 2023First efficacy abstractLead compound reduces spontaneous seizures in mice with chronic epilepsy, per an American Epilepsy Society abstract
- Feb 2024Innobooster grantThird Innobooster grant from Innovation Fund Denmark for the epilepsy programmeDKK 5M
- Jan 2025Series AFirst closing co-led by Angelini Ventures and Invivo Partners€20M
- Sep 2025CEO changeEllen K. Donnelly registered as chief executive from 15 September 2025
- Dec 2025Safety dataMouse and primate safety abstract; phase 1/2 design for 40 adults described
- Nov 2026EIC selectionADMIRE selected for blended finance in the batch covering the May and July 2026 cut-offs
- Early 2027Clinic entryPlanned move of NMT.001 into the clinic, per the companyPlanned
Nature Medicine, 2012; Danish business register via eStatistik; Aalborg University; Neumirna news page and Series A release; American Epilepsy Society abstracts; BioIndustry Association; EIC, 16 November 2026.
The money on the record
Neumirna's funding came in small pieces until 2025. Sunstone invested a €400,000 convertible loan in late 2022, Aalborg University reported. The company announced a $650,000 Michael J. Fox Foundation grant for its Parkinson's work in August 2023 and a third Innobooster grant of DKK 5 million from Innovation Fund Denmark in February 2024. It is one of four partners in PARMED, a Parkinson's consortium with a €1.65 million Eurostars grant, the University of Bordeaux announced in October 2023; that figure is for the whole consortium.
The large step was the Series A. On 8 January 2025 the company announced the first closing of a €20 million round co-led by Angelini Ventures and Invivo Partners, with its seed investor Innovestor's Life Science Fund and other existing investors, as PharmaTimes also reported. The register's owner list now shows HELLERUNG ApS with 25% to 33.33%, Innovestor and Angelini with 15% to 19.99% each, and Invivo Ventures III with 10% to 14.99%.
The filed accounts, summarised by eStatistik from the Danish business register, show what that money did. Equity was negative in the 2022, 2023 and 2024 accounts, reaching minus DKK 18.4 million. In 2025 equity rose to DKK 91.8 million while the net loss grew to DKK 55.8 million, eight times the 2024 loss. The accounts do not disclose revenue, and the reported gross result is negative in every year from 2021 to 2025.
The accounts
The 2025 loss was eight times the 2024 loss
Annual net losses stayed between DKK 5.3M and DKK 8.0M until the Series A, then reached DKK 55.8M in 2025. The accounts do not disclose revenue.
Filed annual accounts, Danish business register, summarised by eStatistik. Values in DKK millions.
The balance sheet
Equity turned positive only after the Series A
Equity was negative in the 2022, 2023 and 2024 accounts and stood at DKK 91.8M at the end of 2025, the year of the €20M Series A first closing.
Filed annual accounts, Danish business register, summarised by eStatistik. Values in DKK millions.
What the EIC part is worth
The EIC has not published individual amounts. Its announcement gives €84 million of proposed grants across the 35 companies, grants of up to €2.5 million each, and says 32 companies will be assessed by the EIC Fund for equity of up to €10 million each. Neumirna had announced no ADMIRE amount by 16 November 2026, CORDIS lists no project for it, and sources reviewed on that date show no EIC Fund investment announced by the company or the EIC.
Why the EU funds it
The award sits where two EU priorities meet. The Commission's life sciences strategy of 2 July 2025 proposes an EU investment plan for multi-country clinical trials and a matchmaking interface between start-ups, industry and investors, and a first-in-human study is the step Neumirna needs next. The company's investors are European: an Italian corporate fund, a Barcelona venture firm and a Finnish fund, per the Series A release. Antisense drugs for the nervous system have already reached European patients, as the spinal muscular atrophy launch Tracik led at Biogen shows; Neumirna is a Danish attempt to apply the same drug class to epilepsy.
What ADMIRE promises and what can be checked
CORDIS has no ADMIRE project yet, so the only statement of the project's aim is its title on the EIC list. The company's December 2025 abstract describes the planned trial: a phase 1/2 study in 40 adults with focal drug-resistant epilepsy, double-blind and placebo-controlled in part 1 and open-label in part 2, to start after repeat-dose toxicology studies in mice and primates are complete.
- Selection for EIC Accelerator blended financeSelectedADMIRE is on the EIC list published 16 November 2026.
- Signed grant agreementPendingExpected within three months of the announcement, per the EIC; no CORDIS record on 16 November 2026.
- Repeat-dose GLP toxicology in mice and primatesPlannedDescribed as planned in the December 2025 abstract; no results published in sources reviewed on 16 November 2026.
- Phase 1/2 trial in 40 adultsNot startedClinic entry planned for early 2027, per the BioIndustry Association notice.
- EIC Fund equityToo earlyThe EIC Fund decides equity separately; no investment announced.
What the company says
A first-in-class RNA drug that targets the cause of drug-resistant epilepsy rather than its symptoms, with "unprecedented preclinical efficacy" and favourable safety margins, ready for the clinic in early 2027.
What the record shows
A 2012 peer-reviewed paper on the target, company-authored conference abstracts on the drug, a €20M Series A, a DKK 55.8M loss in 2025, no disclosed revenue, an EIC selection without a published amount, and no human study reported in sources reviewed on 16 November 2026.
Verdict
Neumirna is a preclinical drug developer with a credible scientific lineage and enough private money to reach a first trial, which is the stage the EIC's blended finance is built for. What has been shown about NMT.001 sits in conference abstracts by its own staff and academic partners, not in a peer-reviewed study, and the primate data include acute neurological effects at higher doses. The test of ADMIRE is whether the 40-patient study starts in 2027 as the company plans; until then, the EIC selection buys time, not proof.
The reporting is based on publicly available sources, listed below.
Sources
- EIC, The European Innovation Council selects 35 deep tech companies for its Accelerator support, 16 November 2026, with list of selected companies
- eStatistik, Neumirna Therapeutics ApS, CVR 41696451, register data and filed accounts 2021 to 2025
- eStatistik, Neumirna Therapeutics ApS, owners, management and board
- Neumirna Therapeutics, company website
- Neumirna Therapeutics, news page
- Neumirna Therapeutics, Series A press release, 8 January 2025
- PharmaTimes, Angelini Ventures co-leads €20 million Series A in Neumirna, 8 January 2025
- Silicon Republic, Neumirna raises €20m, will begin clinical trials for its epilepsy drug, 10 January 2025
- Aalborg University, A new future in RNA therapeutics for neurological disorders, 20 December 2022
- BioIndustry Association, Coulter Partners places Dr Ferenc Tracik as CMO of Neumirna, 20 May 2026
- University of Bordeaux, Eurostars grant awarded to PARMED consortium, 3 October 2023
- Jimenez-Mateos et al., Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects, Nature Medicine, 2012
- American Epilepsy Society, abstract 3.472, 2023
- American Epilepsy Society, abstract 1.529, 2024
- American Epilepsy Society, abstract 2.469, 2025
- American Epilepsy Society, abstract 2.371, 2025
- World Health Organization, Epilepsy fact sheet
- European Commission, life sciences strategy, 2 July 2025
Industry
HealthBiopharmaceuticals
- Focus
- Oligonucleotide therapeutics
- Technologies
- Oligonucleotides
- Keywords
- Drug-resistant epilepsy
- MicroRNA
- Parkinson's disease
- Neurology